RDY 6-K
Dr Reddys Laboratories Ltd (RDY)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
February, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
| Exhibit<br><br>Number | Description of Exhibits |
|---|---|
| 99.1 | Intimation dated February 09,2026 |
| 2 |
|---|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED<br><br>(Registrant) | |||
|---|---|---|---|
| Date: February 09,2026 | By: | /s/ K Randhir Singh | |
| Name: | K Randhir Singh | ||
| Title: | Company Secretary | ||
| 3 | |||
| --- |
Exhibit 99.1
| Dr. Reddy's Laboratories Ltd. |
|---|
| 8-2-337, Road No. 3, Banjara Hills |
| Hyderabad – 500 034, Telangana, India |
| CIN: L85195TG1984PLC004507 |
| Tel: + 91 40 4900 2900 |
| Fax: + 91 40 4900 2999 |
| Email: [email protected] |
| Web: www.drreddys.com |
February 9, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
| Sub: | Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Change in Senior Managerial Personnel |
|---|
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform that Mr. Sushrut Kulkarni has resigned from the position of Global Head of IPDO and Senior Management Personnel of the Company. He will cease to be in employment and as part of Senior Management Personnel of the Company, effective from the close of business hours on May 8, 2026. The resignation letter as received from Mr. Sushrut Kulkarni is annexed herewith.
The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in Annexure enclosed herewith.
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
Encl: as above
Annexure
Details under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
| Sl. No. | Particulars | Details |
|---|---|---|
| 1 | Reason for change viz. ~~appointment, re-appointment,~~ resignation, ~~removal, death or otherwise;~~ | Mr. Sushrut Kulkarni has resigned from the position of Global Head of IPDO and Senior Management Personnel of the Company to explore opportunities outside the Company. |
| 2 | Date of ~~appointment/re-appointment/~~cessation ~~(as applicable) & term of appointment/re-appointment~~ | May 8, 2026 |
| 3 | Brief profile (in case of appointment) | Not applicable |
| 4 | Disclosure of relationships between directors (in case of appointment of a director) | Not applicable |
9^th^ February, 2026
To,
Mr. Erez Israeli
Dr. Reddy’s Laboratories Limited
8-2-337, Road No-3, Banjara Hills,
Hyderbabad-Telangana-500034
Dear Erez,
Sub: Resignation
I am writing to formally resign from my position as Global Head of IPDO and Senior Management Personnel of Dr. Reddy’s Laboratories Limited, effective May 8, 2026, to explore opportunities outside the organisation.
I confirm that I will continue to support the Company during the notice period and ensure a smooth handover of responsibilities to facilitate the transition of my role. I would like to express my sincere appreciation for the opportunity to be part of the organization and wish the Company continued success in future.
Thanking you and regards,
Sushrut Kulkarni